Atlantic Edge Private Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Atlantic Edge Private Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.06K	Hold	1,600	–	–	﹤0.01%	495
2026 Q1	$4.38K	Hold	1,600	–	–	﹤0.01%	472
2025 Q4	$5.92K	Hold	1,600	–	–	﹤0.01%	439
2025 Q3	$4.24K	Hold	1,600	–	–	﹤0.01%	453
2025 Q2	$1.58K	Hold	1,600	–	–	﹤0.01%	477
2025 Q1	$2.3K	Hold	1,600	–	–	﹤0.01%	453
2024 Q4	$3.52K	Buy	+1,600	New	+$3.73K	﹤0.01%	416

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Atlantic Edge Private Wealth Management's ESPR Position: Q2 2026 in Review

Atlantic Edge Private Wealth Management held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 1,600 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #495.

Atlantic Edge Private Wealth Management first reported a position in ESPR in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.92K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Atlantic Edge Private Wealth Management held 1,600 shares of Esperion Therapeutics worth $5.06K as of Q2 2026.
Atlantic Edge Private Wealth Management left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of Atlantic Edge Private Wealth Management's portfolio in Q2 2026, its #495 holding.
Atlantic Edge Private Wealth Management first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 7 quarters since.
Atlantic Edge Private Wealth Management's Esperion Therapeutics position peaked at $5.92K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.